I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience CTAD 2023
Roche and Genentech at

CTAD 2023

October 24 - October 27
Boston, USA
ctad-alzheimer.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 26 / Roche
An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD.
Recent results of anti-amyloid trials have raised the question how best to characterize the relationship between amyloid PET and clinical endpoints. We attempt to address this question through statistical modelling of publicly available data from several anti-amyloid trials.
Neuroscience Alzheimer Disease CTAD-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 25 / Roche and Genentech
Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer’s Disease
Semorinemab is a humanized anti-tau IgG4 monoclonal antibody under investigation as a disease-modifying treatment for Alzheimer’s disease (AD). In a Phase 2 trial for mild-to-moderate AD (Lauriet), patients demonstrated significant reductions in cognitive decline (ADAS-Cog11) relative to placebo, but no changes to the co-primary and secondary endpoints. Plasma and cerebrospinal fluid (CSF) were collected for fluid biomarker assessments. Semorinemab induced dramatic increases in measures of plasma total and phosphorylated tau species, and a reduction in CSF tau species. Changes to a subset of synaptic biomarkers were observed, with annualized reductions in neurogranin and SNAP-25 being greater following semorinemab treatment. Measures of gliosis demonstrated significant increases in CSF YKL-40, but not in the plasma; CSF GFAP was unchanged, but Semorinemab prevented the accumulation of plasma GFAP compared to placebo. These data provide evidence that semorinemab engages tau in the CNS and periphery in a manner consistent with data previously reported in prodromal-to-mild AD patients (Tauriel) and that modulation of extracellular tau levels may impact synaptic biology and moderate reactive astrogliosis.
Neuroscience Alzheimer Disease CTAD-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 25 / Roche
RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a phase II trial based on population PK/PD modeling
RG6289 is a new γ-secretase modulator in development for the treatment of Alzheimer’s disease. Data from the Phase I study after single and multiple dose administration were used to develop a population PK/PD model in order to characterize the relationship between RG6289 concentrations and Aβ42 lowering in plasma. Based on the final population PK/PD model, food did not have any relevant effect on the PD of RG6289. Age effects on PK were taken into account when selecting the final doses for the upcoming Phase IIa study. The three selected doses are covering a broad range of Aβ42 lowering expected to be therapeutically relevant in the very early stages of AD.
Neuroscience Alzheimer Disease CTAD-2023
12:00 PM
Duration 96hrs Boston, USA
Alzheimer's disease linkage to evidence (AD-LINE) study: An analysis of concordance between clinical diagnosis and evidence of AD diagnosis in real-world US claims data
Desilu Glazebrook
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
RG6289, a new γ-secretase modulator for the treatment of Alzheimer’s disease: Dose selection for a phase II trial based on population PK/PD modeling
Agnes Portron
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Baseline risk factors for ARIA-E in the GRADUATE I and II studies of gantenerumab
Paul Delmar
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Assessing health system capacity for delivery of a disease-modifying therapy for Alzheimer’s disease: a multi-country analysis
Nathalie Budd
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:35 PM
Duration 10mins Boston, USA
THE ANTI-AMYLOID BETA “BRAIN SHUTTLE” ANTIBODY TRONTINEMAB RAPIDLY REDUCES AMYLOID PLAQUES IN PARTICIPANTS WITH ALZHEIMER’S DISEASE
Luka Kulic
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Pharmacodynamic Effects of Semorinemab on Biomarkers of Tau, Synaptic Function, and Gliosis in a Phase 2 Trial of Mild-to-Moderate Alzheimer’s Disease
Stephen Schauer
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 96hrs Boston, USA
Measuring changes in longitudinal Tau-PET with [18F]MK-6240: group-level vs individualized ROIs definition
Nick Sidorenko
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 10mins Boston, USA
An exploration of amyloid removal measures in relation to clinical benefit: a review and meta-regression of anti-amyloid trials in AD.
Marzia A. Scelsi (lead author) / Paul Delmar (presenter)
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 96hrs Boston, USA
Automated linguistic metrics from a novel, remote, smartphone-based self-assessment of cued narration and free recall correlate with brain atrophy in language and memory networks in early Alzheimer’s disease
Irma Kurniawan
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.